The oncogene phosphatidylinositol 3′-kinase catalytic subunit α promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma

Cancer Research

Volumn 63, Issue 14, 2003, Pages 4225-4231

  Zhang, Lin ^a,b   Yang, Nuo ^b   Katsaros, Dionyssios ^c   Huang, Wei ^b   Park, Jin Wan ^b   Fracchioli, Stefano ^c   Vezzani, Cristina ^b   De la Longrais, Irene A Rigault ^c   Yao, Weijia ^b   Rubin, Stephen C ^b   Coukos, George ^a,b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN; PROTEIN P 110 ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVE SITE; ENZYME ANALYSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; RNA ANALYSIS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; CATALYTIC DOMAIN; CELL DIVISION; CHROMONES; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MORPHOLINES; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RNA, MESSENGER; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0041672301     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., and Gray, J. W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet., 21: 99-102, 1999.
2. Vivanco, I., and Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2: 489-501, 2002.
3. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science (Wash. DC), 296: 1655-1657, 2002.
4. Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., and Waterfield, M. D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol., 17: 615-675, 2001.
5. Hiles, I. D., Otsu, M., Volinia, S., Fry, M. J., Gout, I., Dhand, R., Panayotou, G., Ruiz-Larrea, F., Thompson, A., Totty, N. F., et al. Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell, 70: 419-429, 1992.
6. Iwabuchi, H., Sakamoto, M., Sakunaga, H., Ma, Y. Y., Carcangiu, M. L., Pinkel, D., Yang-Feng, T. L., and Gray, J. W. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res., 55: 6172-6180, 1995.
7. Knuutila, S., Bjorkqvist, A. M., Autio, K., Tarkkanen, M., Wolf, M., Monni, O., Szymanska, J., Larramendy, M. L., Tapper, J., Pere, H., El-Rifai, W., Hemmer, S., Wasenius, V. M., Vidgren, V., and Zhu, Y. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am. J. Pathol., 152: 1107-1123, 1998.
8. Massion, P. P., Kuo, W. L., Stokoe, D., Olshen, A. B., Treseler, P. A., Chin, K., Chen, C., Polikoff, D., Jain, A. N., Pinkel, D., Albertson, D. G., Jablons, D. M., and Gray, J. W. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res., 62: 3636-3640, 2002.
9. Redon, R., Muller, D., Caulee, K., Wanherdrick, K., Abecassis, J., and du Manoir, S. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res., 61: 4122-4129, 2001.
10. Woenckhaus, J., Steger, K., Werner, E., Fenic, I., Gamerdinger, U., Dreyer, T., and Stahl, U. Genomic gain of PIK3CA and increased expression of p110α are associated with progression of dysplasia into invasive squamous cell carcinoma. J. Pathol., 198: 335-342, 2002.
11. Hui, A. B., Lo, K. W., Yin, X. L., Poon, W. S., and Ng, H. K. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab. Investig., 81: 717-723, 2001.
12. Hui, A. B., Lo, K. W., Teo, P. M., To, K. F., and Huang, D. P. Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int. J. Oncol., 20: 467-473, 2002.
13. Singh, B., Reddy, P. G., Goberdhan, A., Walsh, C., Dao, S., Ngai, I., Chou, T. C., O-Charoenrat, P., Levine, A. J., Rao, P. H., and Stoffel, A. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev., 16: 984-993, 2002.
14. Ma, Y. Y., Wei, S. J., Lin, Y. C., Lung, J. C., Chang, T. C., Whang-Peng, J., Liu, J. M., Yang, D. M., Yang, W. K., and Shen, C. Y. PIK3CA as an oncogene in cervical cancer. Oncogene, 19: 2739-2744, 2000.
15. Zhang, A., Maner, S., Betz, R., Angstrom, T., Stendahl, U., Bergman, F., Zetterberg, A., and Wallin, K. L. Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int. J. Cancer, 101: 427-433, 2002.
16. Arbiser, J. L., Moses, M. A., Fernandez, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H. R., and Folkman, J. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA, 94: 861-866, 1997.
17. Rak, J., Mitsuhashi, Y., Sheehan, C., Tamir, A., Viloria-Petit, A., Filmus, J., Mansour, S. J., Ahn, N. G., and Kerbel, R. S. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res., 60: 490-498, 2000.
18. Jiang, B. H., Agani, F., Passaniti, A., and Semenza, G. L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res., 57: 5328-5335, 1997.
19. Shim, H., Dolde, C., Lewis, B. C., Wu, C. S., Dang, G., Jungmann, R. A., Dalla-Favera, R., and Dang, C. V. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA, 94: 6658-6663, 1997.
20. Baudino, T. A., McKay, C., Pendeville-Samain, H., Nilsson, J. A., Maclean, K. H., White, E. L., Davis, A. C., Ihle, J. N., and Cleveland, J. L. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev., 16: 2530-2543, 2002.
21. Pelengaris, S., Khan, M., and Evan, G. I. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell, 109: 321-334, 2002.
22. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., and Semenza, G. L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol., 21: 3995-4004, 2001.
23. Lopez-Ocejo, O., Viloria-Petit, A., Bequet-Romero, M., Mukhopadhyay, D., Rak, J., and Kerbel, R. S. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene, 19: 4611-4620, 2000.
24. An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., and Neckers, L. M. Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature (Lond.), 392: 405-408, 1998.
25. Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., and Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev., 14: 34-44, 2000.
26. Yuan, A., Yu, C. J., Luh, K. T., Kuo, S. H., Lee, Y. C., and Yang, P. C. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J. Clin. Oncol., 20: 900-910, 2002.
27. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., and Kerbel, R. S. Effect of p53 status on tumor response to antiangiogenic therapy. Science (Wash. DC), 295: 1526-1528, 2002.
28. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (Lond.), 399: 271-275, 1999.
29. Turner, K. J., Moore, J. W., Jones, A., Taylor, C. F., Cuthbert-Heavens, D., Han, C., Leek, R. D., Gatter, K. C., Maxwell, P. H., Ratcliffe, P. J., Cranston, D., and Harris, A. L. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res., 62: 2957-2961, 2002.
30. Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., Gottschalk, A. R., Ryan, H. E., Johnson, R. S., Jefferson, A. B., Stokoe, D., and Giaccia, A. J. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev., 14: 391-396, 2000.
31. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W., and Semenza, G. L. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res., 60: 1541-1545, 2000.
32. Rak, J., Yu, J. L., Kerbel, R. S., and Coomber, B. L. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res., 62: 1931-1934, 2002.
33. Rak, J., Yu, J. L., Klement, G., and Kerbel, R. S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig. Dermatol. Symp. Proc., 5: 24-33, 2000.
34. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/ Akt signaling pathway in Ha-ras-transformed cells through a hypoxia-inducible factor-1 transcriptional element. Blood, 90: 3322-3331, 1997.
35. Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., and Vogt, P. K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ., 12: 363-369, 2001.
36. Jiang, B. H., Zheng, J. Z., Aoki, M., and Vogt, P. K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc. Natl. Acad. Sci. USA, 97: 1749-1753, 2000.
37. Blancher, C., Moore, J. W., Robertson, N., and Harris, A. L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1{α}, HIF-2{α}, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res., 61: 7349-7355, 2001.
38. Chen, E. Y., Mazure, N. M., Cooper, J. A., and Giaccia, A. J. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res., 61: 2429-2433, 2001.
39. Thakker, G. D., Hajjar, D. P., Muller, W. A., and Rosengart, T. K. The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J. Biol. Chem., 274: 10002-10007, 1999.
40. Soldi, R., Mitola, S., Strasly, M., Defilippi, P., Tarone, G., and Bussolino, F. Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor 2. EMBO J., 18: 882-892, 1999.
41. Carmeliet, P., Lampugnani, M. G., Moons, L., Breviario, F., Compernolle, V., Bono, F., Balconi, G., Spagnuolo, R., Oostuyse, B., Dewerchin, M., Zanetti, A., Angellilo, A., Mattot, V., Nuyens, D., Lutgens, E., Clotman, F., de Ruiter, M. C., Gittenberger-de Groot, A., Poelmann, R., Lupu, F., Herbert, J. M., Collen, D., and Dejana, E. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell, 98: 147-157, 1999.
42. Zhang, L., Yang, N., Mohamed-Hadley, A., Rubin, S. C., and Coukos, G. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and antiangiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun., 303: 1169-1178, 2003.
43. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-1 (LY294002). J. Biol. Chem., 269: 5241-5248, 1994.
44. Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., Rubin, S. C., and Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med., 348: 203-213, 2003.
45. Zhang, L., Yang, N., Conejo-Garcia, J. R., Katsaros, D., Mohamed-Hadley, A., Fracchioli, S., Schlienger, K., Toll, A., Levine, B., Rubin, S. C., and Coukos, G. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin. Cancer Res., 9: 264-272, 2003.
46. Zhang, L., Conejo-Garcia, J. R., Yang, N., Huang, W., Mohamed-Hadley, A., Yao, W., Benencia, F., and Coukos, G. Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem. Biophys. Res. Commun., 292: 860-868, 2002.
47. Zhang, L., Yang, N., Garcia, J. R., Mohamed, A., Benencia, F., Rubin, S. C., Allman, D., and Coukos, G. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am. J. Pathol., 161: 2295-2309, 2002.
48. Suzuki, S., Moore, D. H., II, Ginzinger, D. G., Godfrey, T. E., Barclay, J., Powell, B., Pinkel, D., Zaloudek, C., Lu, K., Mills, G., Berchuck, A., and Gray, J. W. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res., 60: 5382-5385, 2000.
49. Gray, J. W., Suzuki, S., Kuo, W. L., Polikoff, D., Deavers, M., Smith-McCune, K., Berchuck, A., Pinkel, D., Albertson, D., and Mills, G. B. Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol. Oncol., 88: S16-S21; discussion S22-S24, 2003.
50. Hu, L., Zaloudek, C., Mills, G. B., Gray, J., and Jaffe, R. B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res., 6: 880-886, 2000.
51. Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A., and Nussbaum, R. L. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase. J. Biol. Chem., 274: 10963-10968, 1999.
52. Ruoslahti, E. Specialization of tumor vasculature. Nat. Rev. Cancer, 2: 83-90, 2002.
53. Shimada, T., Morita, T., Nagai, K., Sato, F., Mori, H., and Campbell, G. R. Morphological changes in spiral artery of the mammalian ovary with age. Horm. Res., 39 (Suppl. 1): 9-15, 1993.
54. Komalavilas, P., Mehta, S., Wingard, C. J., Dransfield, D. T., Bhalla, J., Woodrum, J. E., Molinaro, J. R., and Brophy, C. M. PI3-kinase/Akt modulates vascular smooth muscle tone via cAMP signaling pathways. J. Appl. Physiol., 91: 1819-1827, 2001.
55. Klippel, A., Escobedo, M. A., Wachowicz, M. S., Apell, G., Brown, T. W., Giedlin, M. A., Kavanaugh, W. M., and Williams, L. T. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation. Mol. Cell. Biol., 18: 5699-5711, 1998.
56. Frevert, E. U., and Kahn, B. B. Differential effects of constitutively active phosphatidylinositol 3-kinase on glucose transport, glycogen synthase activity, and DNA synthesis in 3T3-L1 adipocytes. Mol. Cell. Biol., 17: 190-198, 1997.
57. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H., and Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J., 16: 2783-2793, 1997.
58. Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordan, J., Bellacosa, A., Tsichlis, P. N., and Hay, N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev., 11: 701-713, 1997.
59. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
60. Stein, R. C., and Waterfield, M. D. PI3-kinase inhibition: a target for drug development? Mol. Med. Today, 6: 347-357, 2000.
61. Razzini, G., Berrie, C. P., Vignati, S., Broggini, M., Mascetta, G., Brancaccio, A., and Falasca, M. Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J., 14: 1179-1187, 2000.
62. Hu, L., Hofmann, J., Lu, Y., Mills, G. B., and Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res., 62: 1087-1092, 2002.
63. Mills, G. B., Lu, Y., and Kohn, E. C. Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 98: 10031-10033, 2001.